| Summary: | The intestine barrier, the front line of normal body defense, relies on its structural integrity, microbial composition and barrier immunity. The intestinal mucosal surface is continuously exposed to a complex and dynamic community of microorganisms. Although it occupies a relatively small proportion of the intestinal microbiota, <i>Lactobacilli</i> has been discovered to have a significant impact on the intestine tract in previous studies. It is undeniable that some <i>Lactobacillus</i> strains present probiotic properties through maintaining the micro-ecological balance via different mechanisms, such as mucosal barrier function and barrier immunity, to prevent infection and even to solve some neurology issues by microbiota–gut–brain/liver/lung axis communication. Notably, not only living cells but also <i>Lactobacillus</i> derivatives (postbiotics: soluble secreted products and para-probiotics: cell structural components) may exert antipathogenic effects and beneficial functions for the gut mucosal barrier. However, substantial research on specific effects, safety and action mechanisms in vivo should be done. In clinical application of humans and animals, there are still doubts about the precise evaluation of <i>Lactobacilli</i>’s safety, therapeutic effect, dosage and other aspects. Therefore, we provide an overview of central issues on the impacts of <i>Lactobacillus casei</i> (<i>L. casei</i>) and their products on the intestinal mucosal barrier and some diseases and highlight the urgent need for further studies.
|
|---|